Telomere-driven senescence accelerates tau pathology, neuroinflammation and neurodegeneration in a tauopathy mouse model.
Level 5 - mechanism / opinion, no new human data
Non-human animal model study (transgenic mice).
PubMed 41024124 · doi:10.1186/s40478-025-02118-5
What was done
Researchers crossed telomerase RNA component knockout mice (Terc -/-, a model of telomere-induced senescence) with the PS19 P301S tauopathy mouse model. Brain tissue sections and protein extracts from 6- and 9-month-old mice were analyzed using biochemical and molecular assays to assess telomere attrition, cellular senescence markers, tau phosphorylation and truncation, glial activation, and neuronal loss.
What was found
Brains of 6- and 9-month-old Terc -/- mice showed significant telomere attrition and markers of cellular senescence. The introduction of senescence into the tauopathy model led to increased tau phosphorylation (particularly in the hippocampus), increased tau truncation and aggregation, exacerbated astrocyte and microglial activation, and selective neuronal loss in vulnerable brain regions. The abstract reports no numerical values, effect sizes, or p-values.
Why it matters
This work provides mechanistic evidence in a rodent model that cellular senescence can act upstream to drive tau pathology, neuroinflammation, and neurodegeneration. It supports further investigation into senolytic or senescence-targeting strategies for Alzheimer's disease and other tauopathies.
Limits
Findings are restricted to transgenic mouse models and may not fully capture human pathology. The abstract does not report sample sizes (n), quantitative metrics, effect sizes, or cognitive/functional behavioral outcomes.
Cited by
- context Lengthening telomeres reduces neurofibrillary tau tangles in neurons.